Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 3/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653604 | 0.98 | SIGMAR1 (0.44) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL8861016 | 0.94 | SIGMAR1 (0.55) | SIGMAR1CYP1A2EPHX1HPGDKDM5A | |
| SCHEMBL8860836 | 0.92 | SIGMAR1 (0.58) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL8861067 | 0.92 | SIGMAR1 (0.58) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1678409 | 0.89 | — | — | |
| SCHEMBL348935 | 0.87 | EPHX1 (0.44) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL5646902 | 0.87 | EPHX1 (0.44) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL5649837 | 0.85 | EPHX1 (0.41) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL1678868 | 0.83 | SIGMAR1 (0.41) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL1679136 | 0.81 | SIGMAR1 (0.44) | SIGMAR1KDM5APHF8KDM2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | HDHD5, DHX35, HRH3 | SIGMAR1 2928/4885CYP1A2 798/4885KDM1A 2091/4885 |
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | SIGMAR1 539/4885CYP1A2 877/4885KDM1A 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.